ASCO20: ADAURA trial demonstrates potential using osimertinib for late-stage NSCLC

Written by Louis Gautier, Future Science Group

Early results of the ADAURA phase III trial have shown osimertinib could be a viable first-line targeted therapy for stage II-IIIA non-small-cell lung cancer (NSCLC) following complete surgical resection. Patients with EGFR mutations have seen significant improvements in survival, leading to the early unblinding of the trial. Following an announcement at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, osimertinib (Tagrisso®) has been shown to be a viable alternative to chemotherapy in localized NSCLC with EGFR mutations following complete surgical resection. Osimertinib, a third generation EGFR tyrosine kinase inhibitor, has been approved for use in metastatic NSCLC but...

To view this content, please register now for access

It's completely free